Areteia Therapeutics

Closed

Committed to putting asthma patients in better control

Chapel Hill, United States · Founded 2022 · $425.0M raised

Employees
11–50
Founded
2022
Business Model
B2B
Total Funding
$425.0M
Last Round
$75.0M Series AFeb 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Areteia Therapeutics was a clinical-stage biotechnology company developing dexpramipexole, an oral eosinophil-maturation inhibitor, to treat eosinophilic asthma and put patients back in control of their disease. Focused on novel inflammation and immunology therapies, it raised $425M in funding led by ARCH Venture Partners and GV. The company wound down operations in late 2025 amid Phase 3 drug trials.

Summary

Areteia Therapeutics is a Biotech company based in Chapel Hill, United States, founded in 2022. It has raised $425.0M in total across 2 rounds, most recently a $75.0M Series A round in Feb 2024.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A ExtensionFeb 2024
$75.0M

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025
Tessera Therapeutics

Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...

Somerville, United States201–500Biotech, Genomics
Corporate RoundTotal funding$730.0MDec 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Areteia Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/areteia-therapeutics"><img src="https://indexed.vc/api/badge/company/areteia-therapeutics" alt="Areteia Therapeutics on Indexed.vc" width="260" height="76" /></a>